Evidence map›Paper›PMID 42027836›Full record

ArticleFrontiers in medicine2026

Breast cancer recurrence risk prediction based on MIL.

Jinqiu Chen, Huyan Xu

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jinqiu Chen *College of Information Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Huyan Xu *School of Computer Science and Informatics, University of Liverpool, Liverpool, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting breast cancer recurrence risk is a critical clinical challenge. This study investigates the potential of computational pathology to stratify patients using deep learning on routine hematoxylin and eosin (H&E) stained whole-slide images (WSIs). We developed and compared three multiple instance learning (MIL) frameworks-CLAM-SB, ABMIL, and ConvNeXt-MIL-XGBoost-on an in-house dataset of 210 patient cases. The models were trained to predict 5-year recurrence risk, categorized into three tiers (low, medium, high), with ground truth labels established by the 21-gene recurrence score. Features were extracted using the UNI and CONCH pre-trained models. In a 5-fold cross-validation, the modified CLAM-SB model achieved the strongest performance, achieving a mean area under the curve (AUC) of 0.836 and a classification accuracy of 76.2%. Our findings demonstrate the feasibility of using deep learning on standard histology slides for automated, genomics-correlated risk stratification, highlighting a promising pathway toward rapid and cost-effective clinical decision support.

Indexed as

breast cancercomputational pathologydeep learningmultiple instance learningpathological imagesrecurrence risk predictionrisk stratificationwhole-slide images

Identifiers

PMID42027836
PMCPMC13099897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.